Treace Medical Concepts, Inc. (TMCI) stock
TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3031% below fair value
$4.44+0.02 (+0.45%)
Close on Nov 17, 2026Market cap $288.75MP/E –Yield –
Treace Medical Concepts total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Treace Medical Concepts's total debt was $59.21M at Jun 30, 2026. For fiscal 2025 it was $57.33M, up 7.5% from the year before. The highest annual figure on record is $57.33M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.33M | +7.5% |
| FY2024 | Dec 31, 2024 | $53.31M | +0.6% |
| FY2023 | Dec 31, 2023 | $53.01M | +0.6% |
| FY2022 | Dec 31, 2022 | $52.71M | +79.5% |
| FY2021 | Dec 31, 2021 | $29.37M | -5.2% |
| FY2020 | Dec 31, 2020 | $30.98M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $59.21M | +8.5% |
| Q1 FY2026 | Mar 31, 2026 | $57.60M | +7.8% |
| Q4 FY2025 | Dec 31, 2025 | $57.33M | +7.5% |
| Q3 FY2025 | Sep 30, 2025 | $55.33M | +3.9% |
| Q2 FY2025 | Jun 30, 2025 | $54.57M | +2.7% |
| Q1 FY2025 | Mar 31, 2025 | $53.43M | +0.6% |
| Q4 FY2024 | Dec 31, 2024 | $53.31M | +0.6% |
| Q3 FY2024 | Sep 30, 2024 | $53.23M | +0.6% |
| Q2 FY2024 | Jun 30, 2024 | $53.16M | +0.6% |
| Q1 FY2024 | Mar 31, 2024 | $53.08M | +0.6% |
| Q4 FY2023 | Dec 31, 2023 | $53.01M | +0.6% |
| Q3 FY2023 | Sep 30, 2023 | $52.93M | +0.6% |
| Q2 FY2023 | Jun 30, 2023 | $52.86M | +0.6% |
| Q1 FY2023 | Mar 31, 2023 | $52.79M | +79.5% |
| Q4 FY2022 | Dec 31, 2022 | $52.71M | +79.5% |
| Q3 FY2022 | Sep 30, 2022 | $52.64M | +79.5% |
| Q2 FY2022 | Jun 30, 2022 | $52.56M | +79.5% |
| Q1 FY2022 | Mar 31, 2022 | $29.41M | +0.6% |
| Q4 FY2021 | Dec 31, 2021 | $29.37M | -5.2% |
| Q3 FY2021 | Sep 30, 2021 | $29.32M | – |
| Q2 FY2021 | Jun 30, 2021 | $29.28M | – |
| Q1 FY2021 | Mar 31, 2021 | $29.23M | – |
| Q4 FY2020 | Dec 31, 2020 | $30.98M | – |
See a number that looks wrong?